Business Context and Reporting Period
This Form 8-K Current Report was filed by Ecolab Inc. on December 8, 2022. The filing reports a corporate governance event rather than financial results for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on board composition changes.
Material Changes
The primary material change reported is the appointment of a new director:
- Appointment: The Board of Directors approved the appointment of Eric M. Green as a member of the Board of Directors.
- Committee Assignments: Mr. Green will serve on the Compensation and Human Capital Management Committee and the Governance Committee.
- Background: Mr. Green is the President and CEO of West Pharmaceutical Services, Inc., a role he has held since April 2015, and became Chair of that Board in May 2022. He previously held leadership positions at Sigma-Aldrich Corporation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. No specific risks or contingencies related to the appointment were disclosed, other than standard compensation arrangements.
- Compensation: Mr. Green is entitled to participate in Ecolab's regular director compensation arrangements, details of which are incorporated by reference from the 2022 definitive proxy statement.
- Related Party Transactions: The filing states there are no arrangements or transactions between Mr. Green (and his immediate family) and Ecolab requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the effective date of Mr. Green's appointment and his specific committee roles.
- Review the definitive proxy statement filed on March 18, 2022, for details on director compensation arrangements.
- Confirm that no undisclosed related-party transactions exist between the new director and the company.